Anvatabart opadotin

DB18290InvestigationalProtein Based Therapies

Anvatabart opadotin: Overview.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: Arx-788 (anti-her2 mab paf- mmaf toxin oxime conjugate) · gamma1 heavy chain humanized (1-449) [VH humanized (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 A1.4>F (pAF) (121), K120 (217) (121- 218), hinge 1-15 (219 · Immunoglobulin G1 [121-(4-acetylphenylalanine),de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal Amab788 γ1-chain), disulfide with human-Mus musculus monoclonal Amab788 κ-chain, dimer, 121,121′-dioxime · Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated at two engineered sites via a stable
Code names: ARX-788

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anvatabart opadotin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.